https://www.nasdaq.com/press-release/alpine-immune-sciences-announces-participation-in-january-investor-conferences-2022
https://www.nasdaq.com/press-release/alpine-immune-sciences-and-horizon-therapeutics-plc-announce-exclusive-license-and
https://www.nasdaq.com/press-release/alpine-immune-sciences-announces-participation-in-fireside-chat-at-the-4th-annual
https://www.nasdaq.com/press-release/alpine-immune-sciences-provides-corporate-update-and-reports-third-quarter-2021
https://www.nasdaq.com/press-release/alpine-immune-sciences-to-present-alpn-303-data-at-american-college-of-rheumatology
https://www.nasdaq.com/press-release/alpine-immune-sciences-announces-%2491-million-private-placement-2021-09-15
https://www.nasdaq.com/press-release/alpine-immune-sciences-announces-participation-in-september-investor-conferences-2021
https://www.nasdaq.com/press-release/alpine-immune-sciences-provides-corporate-update-and-reports-second-quarter-2021
https://www.nasdaq.com/press-release/alpine-immune-sciences-to-report-second-quarter-2021-financial-results-and-to-present
https://www.nasdaq.com/press-release/alpine-immune-sciences-to-collaborate-with-merck-on-immuno-oncology-study-to-evaluate
https://www.nasdaq.com/press-release/alpine-immune-sciences-announces-first-patient-dosed-in-synergy-alpn-101-phase-2
https://www.nasdaq.com/press-release/alpine-immune-sciences-set-to-join-russell-3000r-index-2021-06-08
https://www.nasdaq.com/press-release/alpine-immune-sciences-announces-alpn-202-clinical-data-presented-at-the-2021-asco
https://www.nasdaq.com/press-release/alpine-immune-sciences-presents-alpn-303-data-during-the-2021-eular-virtual-meeting
https://www.nasdaq.com/press-release/alpine-immune-sciences-appoints-zelanna-goldberg-m.d.-m.a.s.-as-chief-medical-officer
https://www.nasdaq.com/press-release/alpine-immune-sciences-to-host-investor-event-at-2021-asco-virtual-annual-meeting
https://www.nasdaq.com/press-release/alpine-immune-sciences-announces-oral-presentation-at-the-2021-eular-virtual-meeting
https://www.nasdaq.com/press-release/alpine-immune-sciences-provides-corporate-update-and-reports-first-quarter-2021
https://www.nasdaq.com/press-release/alpine-immune-sciences-to-present-alpn-202-clinical-data-at-the-2021-asco-virtual
https://www.nasdaq.com/press-release/alpine-immune-sciences-presents-clinical-and-preclinical-oncology-program-updates-at
https://www.nasdaq.com/press-release/alpine-immune-sciences-provides-corporate-update-and-reports-fourth-quarter-and-0
https://www.nasdaq.com/press-release/alpine-immune-sciences-to-report-fourth-quarter-and-full-year-2020-financial-results
https://www.nasdaq.com/press-release/alpine-immune-sciences-announces-poster-presentations-at-aacr-virtual-annual-meeting
https://www.nasdaq.com/press-release/alpine-immune-sciences-to-participate-in-upcoming-virtual-healthcare-conferences-2021
https://www.nasdaq.com/press-release/alpine-immune-sciences-announces-executive-leadership-addition-and-promotion-2021-01
https://www.nasdaq.com/press-release/alpine-immune-sciences-to-present-at-39th-annual-j.p.-morgan-healthcare-conference
https://www.nasdaq.com/press-release/alpine-immune-sciences-appoints-natasha-hernday-to-board-of-directors-2020-12-11
https://www.nasdaq.com/press-release/alpine-immune-sciences-to-participate-in-fireside-chat-at-the-evercore-isi-3rd-annual
https://www.nasdaq.com/press-release/alpine-immune-sciences-to-participate-in-fireside-chat-at-the-piper-sandler-32nd
https://www.nasdaq.com/press-release/alpine-immune-sciences-reports-third-quarter-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/alpine-immune-sciences-to-report-third-quarter-2020-financial-results-and-provide
https://www.nasdaq.com/press-release/alpine-immune-sciences-to-present-at-oppenheimer-fall-healthcare-life-sciences
https://www.nasdaq.com/press-release/alpine-immune-sciences-to-present-at-h.c.-wainwright-22nd-annual-global-investment
https://www.nasdaq.com/press-release/alpine-immune-sciences-reports-second-quarter-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/alpine-immune-sciences-to-present-at-2020-wedbush-pacgrow-healthcare-virtual
https://www.nasdaq.com/press-release/alpine-immune-sciences-to-report-second-quarter-2020-financial-results-and-provide
https://www.nasdaq.com/press-release/alpine-immune-sciences-announces-%2460-million-private-placement-2020-07-24
https://www.nasdaq.com/press-release/alpine-immune-sciences-announces-first-patient-dosed-in-neon-1-phase-1-trial-of-alpn
https://www.nasdaq.com/press-release/alpine-immune-sciences-and-abbvie-announce-option-and-license-agreement-for-the
https://www.nasdaq.com/press-release/alpine-immune-sciences-announces-alpn-202-poster-presentation-at-aacr-virtual-annual
https://www.nasdaq.com/press-release/alpine-immune-sciences-provides-clinical-update-of-its-phase-1-trial-of-alpn-101-in
https://www.nasdaq.com/press-release/alpine-immune-sciences-presents-preclinical-data-on-novel-dual-baff-april-inhibitory
https://www.nasdaq.com/press-release/alpine-immune-sciences-announces-poster-presentations-at-eular-2020-2020-05-29
https://www.nasdaq.com/press-release/alpine-immune-sciences-to-participate-in-fireside-chat-at-the-jefferies-virtual
https://www.nasdaq.com/press-release/alpine-immune-sciences-reports-first-quarter-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/alpine-immune-sciences-presents-design-of-the-alpn-202-phase-1-study-neon-1-at-aacr
https://www.nasdaq.com/press-release/alpine-immune-sciences-announces-poster-presentation-at-aacr-virtual-annual-meeting-i
https://www.nasdaq.com/press-release/alpine-immune-sciences-provides-corporate-update-and-reports-fourth-quarter-and-full
https://www.nasdaq.com/press-release/alpine-immune-sciences-alpn-101-receives-fda-orphan-drug-designations-for-the
https://www.nasdaq.com/press-release/alpine-immune-sciences-announces-cancellation-of-presentation-and-webcast-at-the
https://www.nasdaq.com/press-release/alpine-immune-sciences-to-present-at-two-upcoming-healthcare-investor-conferences
https://www.nasdaq.com/press-release/alpine-immune-sciences-presents-new-preclinical-data-at-2020-crohns-colitis-congress
https://www.nasdaq.com/press-release/alpine-immune-sciences-announces-poster-presentation-at-2020-crohns-colitis-congress
https://www.nasdaq.com/press-release/alpine-immune-sciences-presents-alpn-101-phase-1-healthy-volunteer-study-data-and
https://www.nasdaq.com/press-release/alpine-immune-sciences-to-participate-in-fireside-chat-at-31st-annual-piper-jaffray
https://www.nasdaq.com/press-release/alpine-immune-sciences-provides-corporate-update-and-reports-third-quarter-2019
https://www.nasdaq.com/press-release/alpine-immune-sciences-presents-new-alpn-101-preclinical-data-at-the-2019-american
https://www.nasdaq.com/press-release/alpine-immune-sciences-presents-new-preclinical-data-at-the-society-for-immunotherapy
https://www.nasdaq.com/press-release/alpine-immune-sciences-announces-oral-presentation-of-alpn-101-at-the-61st-american
https://www.nasdaq.com/press-release/alpine-immune-sciences-completes-enrollment-of-phase-i-study-of-alpn-101-and
https://www.nasdaq.com/press-release/alpine-immune-sciences-announces-upcoming-scientific-presentations-at-sitc-and-acr
https://www.nasdaq.com/press-release/alpine-immune-sciences-to-present-at-2019-ladenburg-thalmann-healthcare-conference
https://www.nasdaq.com/press-release/alpine-immune-sciences-provides-corporate-update-and-reports-full-year-2018-financial
https://www.nasdaq.com/press-release/alpine-immune-sciences-present-two-upcoming-investor-conferences-2019-04-21
